Reese's creator's grandson accuses Hershey of changing recipe

Brad Reese, grandson of H.B. Reese, publicly accused The Hershey Company of substituting original milk chocolate and peanut butter in Reese’s products with cheaper compound coatings and peanut‑butter‑style crème in a Feb. 14 LinkedIn letter, alleging erosion of the brand’s legacy. Hershey pushed back in a Feb. 19 statement, saying Reese’s are made the same way and explaining recipe adjustments enable new shapes and sizes; the company notes ~25 million Reese’s Cups are produced daily. The dispute poses reputational risk that could affect consumer perception of Hershey’s flagship brand, but there are no reported sales, earnings impacts, regulatory actions or litigation at this time.

Analysis

Market structure: A reputational hit to Reese’s primarily benefits value/ private‑label confectioners and premium rivals that can credibly claim authentic ingredients; short‑term share shifts of 1–3ppt in snack aisle share are plausible if headlines persist. Hershey (HSY) retains scale, route‑to‑market and pricing power, so any pricing pressure is likely margin compression of 50–200bp rather than catastrophic demand collapse. Commodity impact: sustained substitution to compound coatings would lower persistent cocoa/ milkfat demand modestly; peanut futures reaction likely muted.

Risk assessment: Tail risks include class actions, mislabeling/regulatory probes, or retailers delisting SKUs — low probability but high impact (3–8% EPS hit over 12 months). Immediate (days) risk is sentiment/volatility spike; short term (1–3 months) is measurable sell‑through weakness; long term (1–3 years) the key risk is brand dilution and lost household penetration. Hidden dependencies: co‑packing contracts, US retail promotional cadence, and international licensing arrangements could amplify outcomes.

Trade implications: Tactical hedge vs finite downside: buying 1–3 month put spreads on HSY or shorting small position sized to 1–2% portfolio is sensible; pair trades (short HSY / long MDLZ) capture relative brand resilience. Options are preferred to define risk: buy spreads to limit cost and exploit expected vol re‑pricing around earnings or Nielsen sell‑through data over next 30–90 days.

Contrarian angles: Consensus hysteria likely overstates durable damage—historical precedents (minor recipe/backlash events at Kraft/Mondelez) show recovery within 2–4 quarters after PR/price actions. A >8% headline‑driven share decline without persistent sell‑through weakness is a buy zone; conversely, sustained weekly sell‑through declines >3% y/y for two consecutive months should trigger stronger downside positioning.

Key Decisions for Investors

• Establish a tactical hedge: buy a 3-month HSY put spread sized to risk ~1% of portfolio (e.g., buy 5% OTM put, sell 10% OTM put) to capture 5–8% downside within 90 days; take profit if HSY drops >10% or after the next earnings release.
• Implement a relative value pair: go long MDLZ (Mondelez) ~2% notional and short HSY ~2% notional for 3–6 months to capture expected relative resilience; rebalance if spread in implied volatility widens >150 bps or if MDLZ issues negative guidance.
• Opportunistic accumulation rule: if HSY falls >8% on headlines but subsequent sell‑through (Nielsen/IRI) shows <3% y/y decline for two consecutive weeks, accumulate HSY to 2–3% portfolio as a 12–24 month value play.
• Trigger‑based monitoring actions (do not act without trigger): track weekly Nielsen/IRI sell‑through, social sentiment (negative mention delta >+150%), HSY short interest increasing >5% absolute, and next earnings/10‑Q within 30–90 days; if two triggers fire, increase hedges to 2.5% portfolio or convert positions to cash.